Methods and pharmaceutical compositions for cardiac regeneration

The adult mammalian heart regeneration is largely prevented by the limited proliferative capacity of the resident cardiomyocytes (CMs). Here, the […]

Trek1/trek2 as targets for the treatment of migraine

Inventors have found that the MT mutation puts an alternative start codon in frame which leads to the translation of a second TRESK fragment. […]

A checkpoint kinase 1 inhibitor sensitises cancer cells to

The present invention relates to the field of cancer treatment. In this study, the inventors sought to investigate whether this antiproliferative […]

Lipopeptide compound for the treatment of pain disorder

The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of […]

Methods and pharmaceutical compositions for the treatment of

The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. In particular, the […]

Pharmaceutical compositions for use in the treatment of brain injuries

The invention is in the field of neuroregenerative medicine. Controlling the fate of neural stem cells represents a key therapeutic strategy in […]

Pyk2-based gene therapy gene therapy attenuates cognitive deficits

In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent […]

Pyk2-based gene therapy attenuates cognitive deficits associated to

In the present invention it is shows that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent […]

Inhibition of usp14 impairs melanoma cell survival and overcomes

The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 […]

Slitrk6 as a target for cancers associated with activation of the mapk

The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the […]